Envestnet Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Envestnet Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,693	Closed	-$258K	–	4942
2026 Q1	$258K	Sell	7,693 -11,282	-59%	-$442K	﹤0.01%	4368
2025 Q4	$879K	Buy	18,975 +11,050	+139%	+$606K	﹤0.01%	3346
2025 Q3	$536K	Buy	7,925 +2,059	+35%	+$153K	﹤0.01%	3716
2025 Q2	$491K	Buy	5,866 +1,453	+33%	+$109K	﹤0.01%	3697
2025 Q1	$315K	Buy	+4,413	New	+$215K	﹤0.01%	3895

Envestnet Asset Management's SLNO Position: Q2 2026 in Review

Envestnet Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 7,693 shares — an estimated $258K sold.

Envestnet Asset Management first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $879K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Envestnet Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Envestnet Asset Management sold 7,693 Soleno Therapeutics shares in Q2 2026, an estimated $258K.
Envestnet Asset Management first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
Envestnet Asset Management's Soleno Therapeutics position peaked at $879K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.